A single ascending dose study evaluating the safety and tolerability of POL6014 in individuals with cystic fibrosis
Phase of Trial: Phase I
Latest Information Update: 24 Oct 2018
At a glance
- Drugs POL 6014 (Primary)
- Indications Cystic fibrosis
- Focus Adverse reactions
- 24 Oct 2018 Status changed from recruiting to completed, according to a Santhera Pharmaceuticals media release.
- 24 Oct 2018 According to a Santhera Pharmaceuticals media release, data been presented at the North American Cystic Fibrosis Conference in October 2018.
- 24 Oct 2018 According to a Santhera Pharmaceuticals media release, the Cystic Fibrosis Foundation (CFF) is providing funding support for the conduct of the safety trials with POL6014.